GCA
RVNC

Genesee Capital Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Genesee Capital Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-70,281
Closed -$1.96M – 120
2021
Q3 		$1.96M Buy
+70,281
New +$2.01M 0.97% 34

Other funds holding RVNC

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Genesee Capital Advisors's RVNC Position: Q4 2021 in Review

Genesee Capital Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2021, closing a stake of 70,281 shares — an estimated $1.96M sold.

Genesee Capital Advisors first reported a position in RVNC in Q3 2021 and held it in 1 quarter. The position peaked at $1.96M in Q3 2021. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2021.

  • Genesee Capital Advisors reported no remaining Revance Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Genesee Capital Advisors sold 70,281 Revance Therapeutics, Inc. shares in Q4 2021, an estimated $1.96M.
  • Genesee Capital Advisors first reported a position in Revance Therapeutics, Inc. in Q3 2021 and held it in 1 quarter.
  • Genesee Capital Advisors's Revance Therapeutics, Inc. position peaked at $1.96M in Q3 2021.
  • 151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2021.

Based on Genesee Capital Advisors's 13F filing for Q4 2021, filed 25 Jan 2022.